Clinical Trials Directory

Trials / Completed

CompletedNCT02415374

Bioavailability and Metabolism of Avenanthramide: a Novel Oat Phytochemical

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
16 (actual)
Sponsor
PepsiCo Global R&D · Industry
Sex
All
Age
20 Years – 45 Years
Healthy volunteers
Accepted

Summary

The purpose of the study is to examine whether orally ingested oat avenanthramides (AVA) in oat flour cookies are bioavailable in humans by measuring plasma and urine concentrations of AVAs and their potential metabolites after ingestion. The blood and urine concentrations will be quantified at several different time points after the oat flour cookies are consumed to characterize the "concentration-time profile".

Conditions

Interventions

TypeNameDescription
OTHERAvenanthramidesAVAs are a group of diphenolic acids that are found only in oats (Avena sativa). In this study, each dietary group of subjects will receive three cookies made with oat flour containing high-AVA (H-AVA, 229.56 mg/kg) and low-AVA (L-AVA, 32.69 mg/kg).

Timeline

Start date
2015-01-05
Primary completion
2015-07-15
Completion
2015-07-15
First posted
2015-04-14
Last updated
2021-03-10

Source: ClinicalTrials.gov record NCT02415374. Inclusion in this directory is not an endorsement.

Bioavailability and Metabolism of Avenanthramide: a Novel Oat Phytochemical (NCT02415374) · Clinical Trials Directory